Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

LOSS PER SHARE (Tables)

9 Months Ended

Jun. 30, 2015

A summary of the net loss and shares used to compute net loss per share for the three months ended June 30, 2015 and 2014 is as follows:

	Three months ended June 30,
	2015			2014
Net loss for computation of basic net loss per share:
From continuing operations	$	(536,100	)	$	(1,017,700	)
From discontinued operations		(700	)		(1,100	)
Net loss	$	(536,800	)	$	(1,018,800	)
Basic and diluted net loss per share:
From continuing operations	$	(0.01	)	$	(0.01	)
From discontinued operations		(0.00	)		(0.00	)
Basic net loss per share	$	(0.01	)	$	(0.01	)

Basic and diluted weighted average shares outstanding		101,667,409			100,573,956

Anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Convertible debt		2,126,111			-
Warrants		781,524			1,100,794
Options		12,625,686			11,992,499

A summary of the net loss and shares used to compute net loss per share for the nine months ended June 30, 2015 and 2014 is as follows:

	Nine months ended June 30,
	2015			2014
Net loss for computation of basic net loss per share:
From continuing operations	$	(2,105,100	)	$	(1,821,300	)
From discontinued operations		(2,500	)		(4,400	)
Net loss	$	(2,107,600	)	$	(1,825,700	)
Basic and diluted net loss per share:
From continuing operations	$	(0.02	)	$	(0.02	)
From discontinued operations		(0.00	)		(0.00	)
Basic net loss per share	$	(0.02	)	$	(0.02	)

Basic and diluted weighted average shares outstanding		101,667,409			98,546,223

Anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Convertible debt		1,854,618			-
Warrants		841,192			1,222,450
Options		12,563,059			11,768,663